



Carl H. Coleman* 
It has been almost thirty years since federal regulations 
governing research with human subjects were first developed.  Since 
that time, the world of biomedical research has changed dramatically.  
Not only has the amount of research increased exponentially,1 but 
the context in which research is conducted also has changed.  Twenty 
years ago, medical research was virtually the exclusive province of 
academic medical centers, which designed, conducted, and reported 
on studies financed primarily by the National Institutes of Health.  
Today, research occurs in a broad range of nonacademic settings, 
including for-profit contract research organizations, community 
hospitals, and private physicians’ offices.  In addition, an increasingly 
large portion of research funding comes from private sources.  This 
shift away from an academic model of scientific research to a system 
more closely aligned with private commercial interests has 
complicated the process of research oversight, by both reducing the 
transparency of the research enterprise and increasing the 
prevalence of conflicts of interest. 
In November 2001, Seton Hall Law School, Seton Hall University 
Graduate School of Medical Education, and the American Society of 
Law, Medicine & Ethics sponsored a day-long symposium to explore 
the legal, ethical, and public policy implications of the shift in 
research away from academic medical centers.  Supported by a 
generous grant from the law firm of Gibbons Del Deo Dolan 
Griffinger & Vecchione, the symposium brought together leaders in 
the fields of law, medicine, and bioethics, many of whom have 
contributed papers to this issue of the Seton Hall Law Review. 
The paper by Bernard Lo and Michelle Groman of the 
University of California at San Francisco Medical Center, which 
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expands on Dr. Lo’s keynote address at the beginning of the 
symposium, highlights one of the most significant deficiencies in the 
current regulatory regime—the limited applicability of federal 
human subject protections to research that is not funded by the 
federal government.2  While some privately-funded research is subject 
to federal regulatory oversight, either because it involves products 
regulated by the Food and Drug Administration or because it takes 
place in institutions that have signed multiple project assurances with 
the federal government, a significant proportion of privately-funded 
research fits into neither of these categories.3  One of the most 
important recommendations of the National Bioethics Advisory 
Commission (NBAC), therefore, was its call for a uniform system of 
federal regulation for all human subject research, regardless of 
source of funding.4  In addition to discussing NBAC’s rationale for 
expanding federal jurisdiction over research, Lo and Groman’s paper 
also addresses several other important NBAC recommendations, 
including those designed to reduce unnecessary regulation of low-risk 
activities; to increase the proportion of outside members of 
institutional review boards (IRBs), the committees that review and 
approve research protocols under the federal regulations; to reform 
the requirements for waiving informed consent to research; and to 
provide greater guidance for IRBs’ process of assessing research risks. 
One of the challenges of overseeing research conducted in 
nonacademic settings is identifying an appropriate body to review 
and approve research protocols.  As research increasingly moves away 
from academic medical centers, many of the settings in which 
research is conducted do not have IRBs.  David Forster’s paper 
examines a type of organization that has emerged to fill this void—
the independent institutional review board.5  These organizations, 
which include the company for which Mr. Forster serves as general 
counsel, Western Institutional Review Board, operate separate from 
and unaffiliated with institutions that conduct research activities.  Mr. 
Forster identifies several concerns that have been raised about 
independent IRBs and offers suggestions for addressing these 
concerns, including procedures for minimizing the influence of 
conflicts of interest.  In addition, he argues that independent IRBs 
offer important advantages over traditional IRBs in several respects. 
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The issue of conflicts of interest is the subject of an extensive 
analysis by Mark Barnes and Patrik S. Florencio, both lawyers with the 
law firm of Ropes & Gray in New York.6  Financial conflicts of interest 
“lie at the core of ethical issues surrounding clinical trials,” Barnes 
and Florencio argue, “and the anecdotal evidence is that these 
conflicts are widespread.”7  The potential for commercial interests to 
influence the integrity of research is the result of more than simply 
private sponsorship of particular studies.  Researchers may have 
financial investments in the drugs or devices under investigation, or 
they may own stakes in the companies that are sponsoring their 
studies.  In addition, researchers may receive stipends, speaking and 
consulting fees, and other gifts from research sponsors.  The 
potential influence of financial considerations is most apparent in 
for-profit organizations involved in research, such as contract 
research organizations and site management organizations, which 
“are beholden to their shareholders and less encumbered by 
academic ideals.”8  Barnes and Florencio provide a careful analysis of 
the current federal regulations’ application to conflicts of interest, 
identify their gaps, and describe several proposed approaches to 
reforming the system. 
Nancy Dubler’s commentary offers a broad perspective on the 
ethical challenges raised by the changing research environment.9  Of 
particular concern to Dubler is the process of obtaining the informed 
consent of individuals who enroll in research protocols.  Criticizing 
the lengthy, legalistic, and often incomprehensible consent forms 
currently in use, she argues that the informed consent process must 
“engage[] the subject on an escalating plane of complexity and 
abstraction.”10  Real reform, she argues, will require a significant 
investment of time and money, and those who profit from research 
must be willing to foot the bill. 
While the focus of most of the papers in this issue is research 
outside of academic medical centers, Nancy King’s examination of 
clinical innovation reminds us that the use of untested medical 
interventions within academic settings also may evade effective 
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oversight.11  The reason stems from the definition of research under 
the federal regulations, which applies only to “systematic 
investigation[s] . . . designed to develop or contribute to 
generalizable knowledge.”12  Because the use of untested medical 
interventions in the treatment of individual patients generally lacks 
“the theoretical and empirical preclinical groundwork that 
characterizes the search for knowledge generalizable beyond an 
individual patient,”13 King explains, it is not considered research, and 
therefore need not be submitted for IRB review.  King argues that, 
despite this definitional problem, clinical innovation and research 
share important similarities, including “lack of data, lack of 
experience, and often, significant imbalances between benefits and 
burdens.”14  Indeed, she argues that innovative treatments may 
actually involve greater uncertainty than research, as research must 
be supported by preclinical data, while the basis for innovation might 
simply be “reasoning and intuition alone.”15  Accordingly, she argues 
that for most, if not all, innovations, the type of prior review and 
standardized informed consent processes that govern research would 
be appropriate. 
The papers in this issue highlight both the promises and perils 
of the new direction in which biomedical research is heading.  On 
the one hand, new sources of funding and incentives, greater access 
to potential subjects, and innovative collaborations between 
government, industry, and academia have created enormous 
opportunities for scientific advances.  On the other hand, because 
our regulatory system has failed to keep pace with many of these 
changes, much of this new research occurs with only minimal 
oversight, creating risks for both individual subjects and the integrity 
of the research enterprise itself.  Closing these gaps presents an 
important challenge to policy makers in the years ahead. 
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